Pure red-cell aplasia "epidemic" - Mystery completely revealed?

Peritoneal Dialysis International

Volumn 27, Issue SUPPL. 2, 2007, Pages

  Locatelli, Francesco ^a   Del Vecchio, Lucia ^b   Pozzoni, Pietro ^a  

^a A MANZONI HOSPITAL   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Anemia; Anti erythropoietin antibodies; Chronic kidney disease; Cold chain; Erythropoiesis stimulating agents; Immunogenicity; Pure red cell aplasia

Indexed keywords

ALBUMIN; GLYCINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; POLYSORBATE 80; RECOMBINANT ERYTHROPOIETIN;

CONFERENCE PAPER; DRUG EXPOSURE; DRUG FORMULATION; DRUG STORAGE; DRUG STRUCTURE; EPIDEMIC; HUMAN; IMMUNOGENICITY; INCIDENCE; LEACHING; MICELLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DENATURATION; PURE RED CELL ANEMIA; RISK FACTOR; SYRINGE; UNITED STATES;

CHEMISTRY, PHARMACEUTICAL; DRUG CONTAMINATION; DRUG STORAGE; ERYTHROPOIETIN, RECOMBINANT; HUMANS; RED-CELL APLASIA, PURE; RISK FACTORS; RUBBER; SYRINGES;

EID: 35748959960     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Garcia JF, Clemmons G. The radioimmunoassay of erythropoietin. In: Lawrence JH, ed. Recent Advances in Nuclear Medicine. Vol. VI. New York: Grune and Stratton; 1983: 19-40.
2. Bergrem H, Danielson BG, Eckardt KU, Kurtz A, Stridsberg M. A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. In: Bauer C, Koch KM, Scigalla P, Wieczorek L, eds. Erythropoietin: Molecular Physiology and Clinical Applications. New York: Marcel Dekker; 1993: 265-73.
3. Peces R, de la Torre M, Alcàzar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 1996; 335:523-4.
4. Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 1997; 47:331-5.
5. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346:469-75.
6. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002; 346:1584-6.
7. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, et al., for the European Renal Association-European Dialysis and Transplant Association. Erythropoietic proteins and antibody-mediated pure red cell aplasia: where are we now and where do we go from here? Nephrol Dial Transplant 2004; 19:288-93.
8. Summary of PRCA case reports (Press release). Raritan, NJ: Johnson & Johnson Pharmaceutical Research and Development LLC; n.d. [Available at: www.jnjpharmarnd.com/company/n-casereports.html; accessed 22 April 2007]
9. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351:1403-8.
10. Locatelli F, Del Vecchio L. Pure red cell aplasia secondary to treatment with erythropoietin. Artif Organs 2003; 27: 755-8.
11. Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aptasia. J Am Soc Nephrol 2004; 15:398-406.
12. Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 2004; 363: 1768-71.
13. Weber G, Gross J, Kromminga A, Loew HH, Eckardt KU. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephol 2002; 13: 2381-3.
14. Lisowska E. The role of glycosylation in protein antigenic properties. Cell Mol Life Sci 2002; 59:445-45.
15. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998; 100:79-89.
16. Sikole A, Spasovski G, Zafirov D, Polenakovic M. Epoetin omega for treatment of anemia in maintenance hemodialysis patients. Clin Nephrol 2002; 57:237-45.
17. Egrie JC, Browne KJ. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16(Suppl 3):3-13.
18. Hermeling S, Schellekens H, Crommelin DJ, Jiskoot W. Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? Pharm Res 2003; 20:1903-7.
19. Zinkernagel RM. Uncertainties - discrepancies in immunology. Immunol Rev 2002; 185:103-25.
20. Villalobos AP, Gunturi SR, Heavner GA. Interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions. Pharm Res 2005; 22: 1186-94.
21. Sharma B, Bader F, Templeman T, Lisi P, Ryan M, Heavner GA. Technical investigations into the cause of the increased incidence of antibody-mediated pure red cellaplasia associated with Eprex. Eur J Hospital Pharm 2004; 5:86-91.
22. Ryan MH, Heavner GA, Brigham-Burke M, McMahon F, Shanahan MF, Gunturi SR, et al. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin. Int Immunopharmacol 2006; 6:647-55.
23. Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol 2006; 24:613-14.
24. Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosmilars. Nephrol Dial Transplant 2006; 21(Suppl 5):v13-16.